Zilvetrigine is a sodium channel blocker. Zilvetrigine can be used as analgesics.

Quinacainol dihydrochloride (PK 10139 dihydrochloride) is the dihydrochloride salt form of Quinacainol.

Olisutrigine bromide is a sodium channel blocker, which can be used as analgesics.

N-Hydroxy riluzole is a metabolite of the antiglutamatergic agent Riluzole.

ETD001 is a long-acting ENaC inhibitor, with an IC50 of 57.5 nM in cultured HBE cells. ETD001 can be used in the study for cystic fibrosis.

ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy exhibits low nanomolar cytotoxicity in ERα+ breast cancer cell lines (IC50 = 5-25 nM) through induction of necrosis. ErSO-TFPy exhbits antitumor efficacy in mouse models.

DAPI (Compound 3) is an acid-sensing ion channel 3 (ASIC3) inhibitor. DAPI binds to ASIC3 and blocks the channel function. DAPI can be used in the study of chronic pain treatment.

CL-424032 is a sodium channel inhibitor.

CAY10568 is a compound based on QX-314 and a linker. MC-PEG2-VA-PAB-Exatecan can be used for synthesis of ADCs.

10,11-Dihydroxycarbamazepine is a metabolite of the anticonvulsant Carbamazepine. Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker.

(R)-(+)-Bupivacaine hydrochloride is a voltage-gated sodium channel inhibitor. (R)-(+)-Bupivacaine hydrochloride can selectively block the voltage-gated sodium channels on nerve cell membranes, inhibit the influx of sodium ions, and thus prevent the generation and conduction of nerve impulses, exerting local anesthetic activity. (R)-(+)-Bupivacaine hydrochloride can be used in research of acute pains.

rel-Licogliflozin is a relative configuration of Licogliflozin.

Olorigliflozin is a sodium glucose co-transporter inhibitor with anti-hyperglycemic effects.

Pantoprazole sulfone is a metabolite of the gastric H+/K+ ATPase pump inhibitor Pantoprazole. AR-13503 is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research.

N3-Methyl pantoprazole is an impurity of Pantoprazole-induced stereotyped behaviors and emesis, inhibits discriminative avoidance behavior, and induces catalepsy in rats models.

4-Hydroxy omeprazole sulfide is a metabolite of the proton pump inhibitor Omeprazole.

2-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative that inhibits the proton pump (H+/K+-ATPase), thereby reducing gastric acid secretion. 2-(Trifluoromethyl)cinnamic acid also improves delayed gastric emptying and can be used in research on gastric diseases such as acute gastritis and gastric ulcers.

Tetramisole is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure.

SKP-451 is an ATP-sensitive potassium (K+) channel agonist. SKP-451 activates the ATP-sensitive K+ channels, promotes the efflux of K+, causes membrane hyperpolarization, and inhibits the influx of Ca2+, thereby relaxing the vascular smooth muscle. SKP-451 relaxs the canine coronary artery, rabbit basilar artery, and vertebral artery. SKP-451 also reduces the mean arterial blood pressure of conscious spontaneously hypertensive rats (SHR). SKP-451 is promising for research of cardiovascular diseases.

Opakalim is the activator for potassium channel and exhibits antiepileptic activity.

ONO-TR-772 (VU6018042) is a selective TREK inhibitor (IC50: 15 nM). ONO-TR-772 enhances recognition memory in the MK-801-stimulated NOR mouse model. ONO-TR-772 can be used in the study of diseases related to cognitive impairment.

ONO-2920632 is an orally active and central nervous system (CNS)-penetrant TREK activator, with EC50 values of 0.3 µM and 2.8 μM for TREK-1 and TREK-2, respectively. ONO-2920632 exhibits selectivity for other K2P channels (>91-fold selective versus TASK1, TASK2, TASK3, TRAAK, and TWIK2; 31-fold selective versus TRESK). ONO-2920632 possesses analgesic effects and can be used in research on pain, migraine, and neurological disorders.

Mephetyl tetrazole is a potassium channel Kv1.5 blocker, with an IC50 of 330 nM. Mephetyl tetrazole can be used for the research of cancer.

Lumula (Maxeyprost) is an ethyl amide derivative of Unoprostone. DG013B formate has weak affinity for ERAP1 and ERAP2 and is often used as a negative control to study the binding properties of DG013A and its analogues to ERAP1 and ERAP2.

GPV574 is a derivative of the antiarrhythmic compound propafenone, capable of inhibiting HERG channels (IC50 = 5.04 μM).

Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC50 of 1.2 nM. Ebio3 binds to the KCNQ2 channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy.

Ebio2 is a potent KCNQ2 activator.

E-4031 free base is a selective hERG potassium channel blocker for use in class III anti-arrhythmic studies.

BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects.

(-)-KCC2 blocker 1 is an enantiomer of KCC2 blocker 1 containing an acetylenic fluorobenzene substituent in the lower side chain.